Tag:
legislation
Latest Headlines
Latest Headlines
Law firm brings logistics savvy to Miami
Atlanta-based law concern Arnall Golden Gregory is opening a Miami, FL, office focused on global logistics and supply chain, including the peculiarities of the pharma industry. The office will be...
Pfizer, PhRMA back SOPA amid online protests
With dozens of websites blocked in protest of new anti-piracy legislation, Pfizer ( $PFE ) and PhRMA are among the intellectual-property champions that are lobbying for, rather than against, the
Bill cites fakes dangers, ups penalties
Increased jail time and financial penalties for drug counterfeiters are the subject of a bill proposed by U.S. legislators. The Counterfeit Drug Penalty Enhancement Act is a bipartisan proposal
Senate bill would nix 180-day generics exclusivity
Here's one way to curb pay-for-delay patent settlements: Broaden the field of successful patent challengers. A bill set for introduction in the U.S. Senate would amend the Hatch-Waxman Act, which
Questionable timing: House pushes biotech tax breaks
Against all odds, a bipartisan House group is pushing tax benefits for biotech as well as pharma and medical device companies. The legislation, as currently envisioned, is two-pronged, says
Senators advocate blockbuster remedy for rare drug woes
Lawmakers will soon get a chance to start pondering a bill that would dangle some blockbuster cash as an incentive to developers to take on the risk of developing new therapies for rare children's
Conn. AG backs pharma-gift limits
For the second time in the past two years, Connecticut Attorney General Richard Blumenthal is urging legislation that requires strict limits and disclosure of gifts from drugmakers to doctors who may
Biosimilar debate focuses on key lawmaker
Palo Alto Democrat Rep. Anna Eshoo has been a key sponsor of the bill backing 12 years of data exclusivity for biologics, a position dearly loved by the 2,000 biomedical companies in California. But
Genentech's biosimilar lobbying blitz blasted by NYT
In a move designed to demonstrate bipartisan support for provisions in a healthcare bill that includes 12 years of market exclusivity for biologics, Genentech was able to persuade some 22 Republicans
Biotech dodges a bullet
There's a lot in the new House reform bill the biopharma industry will fight. A mandated rebate on drugs for dual-eligibles--seniors who qualify for both Medicare and Medicaid--would cost
